Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($1.14), $0.08 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $25.12 million versus the consensus estimate of $14.87 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.